Eloxx PharmaceuticalsELOX
13F holders, Q2 2026 (June 30)22holders
$13.88avg. 13F price*
At the end of Q2 2026, 22 institutions reported holding Eloxx Pharmaceuticals Inc. (ELOX) in their 13F filings. The largest holders were Samsara Biocapital, LLC ($5.6M), Nantahala Capital Management, LLC ($5.6M) and EcoR1 Capital, LLC ($5.6M).
- Company
- Eloxx Pharmaceuticals Inc.
- CUSIP
- 29014R301
- Latest filing quarter
- Q2 2026
Total Exit/New Position Q2 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 22 | $34.7M |
| Exits | 0 | $0 |
Ownership 22 holders
| Samsara Biocapital, LLC | 0.46% | New | 400,000 | $5.6M |
| Nantahala Capital Management, LLC | 0.34% | New | 400,000 | $5.6M |
| EcoR1 Capital, LLC | 0.28% | New | 400,000 | $5.6M |
| Siren, L.L.C. | 0.11% | New | 400,000 | $5.6M |
| Aberdeen Group plc | 0.01% | New | 400,000 | $5.6M |
| Stonepine Capital Management, LLC | 4.20% | New | 397,160 | $5.5M |
| Vanguard Capital Management LLC | 0.00% | New | 78,680 | $1.1M |
| Vanguard Fiduciary Trust Co. | 0.00% | New | 10,602 | $147K |
| Seven Grand Managers, LLC | 0.01% | New | 10,000 | $139K |
| Morgan Stanley | 0.00% | New | 1,544 | $21K |
| Vanguard Global Advisers, LLC | 0.00% | New | 718 | $10K |
| UBS Group AG | 0.00% | New | 637 | $9K |
| Wells Fargo & Company | 0.00% | New | 126 | $2K |
| Pioneer Family Office, LLC | 0.00% | New | 96 | $1K |
| Royal Bank of Canada | 0.00% | New | 98 | $1K |
| Altshuler Shaham Ltd | 0.00% | New | 25 | $347 |
| Barclays PLC | 0.00% | New | 12 | $167 |
| Towne Trust Company, N.A | 0.00% | New | 5 | $69 |
| Citigroup Inc. | 0.00% | New | 4 | $56 |
| Activest Wealth Management | 0.00% | New | 4 | $56 |
| SBI Securities Co., Ltd. | 0.00% | New | 2 | $28 |
| Point Nemo Capital, LLC | 0.00% | New | 1 | $14 |
"% of holder's portfolio" is ELOX's weight in each manager's 13F, not the share of Eloxx Pharmaceuticals Inc. the manager owns.